![](/img/cover-not-exists.png)
A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses
Jiri Beran, Ibrahim A. Abdel-Messih, Jolana Raupachova, Lenka Hobzova, Elena FragapaneVolume:
32
Year:
2010
Language:
english
Pages:
12
DOI:
10.1016/s0149-2918(11)00024-5
File:
PDF, 137 KB
english, 2010